undamentalytics Newsletter
Sign in

Veradermics, Inc (MANE) stock

Add to watchlist

Add holding +

NYSE: MANE NYSE Biotechnology Next results ~November 12, 2026

Veradermics, Inc is a US-listed company in the biotechnology industry. Its financial year ends in December.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders5 buying, 4 selling26 purchases and 15 sales by directors and officers, last 12 monthsInsider trades
  • Funds135 adding, 33 cuttingOf 41 active managers that changed their stake, 29 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Next results ~November 12, 2026 (estimated)

Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 10% in the quarter to 2026-06-30.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Veradermics, Inc's latest figures clears our strength thresholds.

Things to watch

  • Volatile shares. Over the past year the shares showed annualised volatility of 92% and a beta of 1.0 against the S&P 500.
  • Heavily shorted. 13.6% of the shares available to trade are sold short (3.9 days of average volume to cover).

Latest results

Earnings per share
-$0.58 against an average estimate of -$0.64: beat by 9.6%
Share reaction
-1.5% in the first session after the results on August 11, 2026, against -0.1% for the S&P 500
Next report
November 12, 2026; average EPS estimate -$0.62

Veradermics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-7.3%
  • 1 week-5.7%
  • 1 month+10.9%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Earnings

Last results
August 11, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Insider trade
  3. Insider trade
  4. Insider trade
  5. Insider trade
  6. Results
  7. Announcement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Veradermics, Inc valuation models and calculator

No model value for Veradermics, Inc at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 12, 2026, before the open. Analysts expect revenue of $0 and EPS of −$0.62 (range −$0.74 to −$0.51) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$2.87 +97% — 0%
Next −$2.64 +8% $9m 0%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +0.9% on 90 days ago. In the last 30 days, 2 analysts raised Veradermics, Inc's forecast and 0 cut it.

Consensus EPS forecast Veradermics, Inc, last 90 days
−$4.00 −$3.00 −$2.00 −$1.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$2.84 Current fiscal year, 60 days ago: −$2.94 Current fiscal year, 30 days ago: −$2.87 Current fiscal year, 7 days ago: −$2.87 Current fiscal year, Now: −$2.87 −$2.87 Next fiscal year, 90 days ago: −$3.05 Next fiscal year, 60 days ago: −$2.69 Next fiscal year, 30 days ago: −$2.69 Next fiscal year, 7 days ago: −$2.69 Next fiscal year, Now: −$2.64 −$2.64

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$2.84−$3.05
60 days ago −$2.94−$2.69
30 days ago −$2.87−$2.69
7 days ago −$2.87−$2.69
Now −$2.87−$2.64

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.64 −$0.58 +9.6%
Dec 2025 −$18.24 −$104.54 −473.1%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

7 analysts, Oct 2026
Buy7100%
Hold00%
Sell00%

Monthly trend

  1. Oct 2026167
  2. Sep 2026167
  3. Aug 2026167
  4. Jul 2026167

Counts of recommendations published by analysts covering Veradermics, Inc, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
13.6%
of tradable shares
Days to cover
3.92
at average volume
Short interest, 1 month
−10%
to October 15, 2026
Held by institutions
99%
of shares
Held by insiders
2.5%
of shares
Employees
37
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Price behaviour

52-week range
Not enough history
From 52-week high
—
vs 50-day average
+12.5%
vs 200-day average
—
Volatility (1 year)
92%
Beta vs S&P 500
1.03

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
1 up, 3 down
typical move ±14.5%
After a week
2 up, 2 down
typical move ±19.2%
After a month
2 up, 2 down
typical move ±33.6%
Results releasedNext dayS&P 500 next day5 days21 days
August 11, 2026 −1.5% −0.1% +0.5% −11.4%
May 12, 2026 −0.9% +0.4% −7.5% −12.7%
April 27, 2026 +52.0% −0.3% +55.2% +47.6%
March 30, 2026 −3.6% +2.6% −13.5% +62.6%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms . Generated November 3, 2026. Definitions in our methodology.

Who owns it

Funds buying and selling
Reported value
$4.2B
Institutions reporting
164
Shares held vs prior quarter
▲ 30.8%
Positions opened / closed
93 / 14

Top buyers and sellers, Q2 2026: 135 institutions bought and 33 sold ; the biggest buyer was Deep Track Capital, LP (+1.5M shares) and the biggest seller Adage Capital Partners Gp, L.L.C (−550K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Montanova Capital, LLC $513M 4.2M 12.2% 0.0%
FMR LLC $394M 3.2M 9.4% ▲ 78.8%
Sr One Capital Management, LP $295M 2.4M 7.0% 0.0%
Deep Track Capital, LP $246M 2.0M 5.9% ▲ 300.0%
Citadel Advisors LLC $231M 1.9M 5.5% ▲ 2.9%
Siren, L.L.C. $204M 1.7M 4.9% ▲ 10.0%
Blackrock, Inc. $196M 1.6M 4.7% ▲ 464.0%
Viking Global Investors LP $192M 1.6M 4.6% ▼ 7.6%
Jpmorgan Chase & Co $144M 1.2M 3.4% ▲ 19.4%
Aberdeen Group PLC $135M 1.1M 3.2% ▲ 4.0%
D. E. Shaw & Co., Inc. $125M 1.0M 3.0% ▲ 655.2%
Vanguard Capital Management LLC $107M 869K 2.5% ▲ 24.2%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Veradermics, Inc's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $58.1M 26 trades by 5 insiders, last 12 months Insider sales History → $103M 15 trades by 4 insiders · 12% under pre-set plans
Net ▼ $45M net selling
Insider Date Trade Shares Price Value
Averill Master Fund, Ltd. Director August 19, 2026 Sell 59,399 $107.25 $6.4M
Averill Master Fund, Ltd. Director August 19, 2026 Sell 690,601 $107.25 $74.1M
Waldman Reid Alexander Chief Executive Officer August 17, 2026 Sell pre-set plan 249 $111.28 $27,709
Waldman Reid Alexander Chief Executive Officer August 17, 2026 Sell pre-set plan 3,000 $109.38 $328,140
Waldman Reid Alexander Chief Executive Officer August 17, 2026 Sell pre-set plan 27,490 $108.45 $3M
Waldman Reid Alexander Chief Executive Officer August 17, 2026 Sell pre-set plan 25,234 $107.53 $2.7M
Waldman Reid Alexander Chief Executive Officer August 17, 2026 Sell pre-set plan 11,527 $106.72 $1.2M
Durso Timothy August Chief Technical Officer August 17, 2026 Sell pre-set plan 2,348 $109.34 $256,730
Durso Timothy August Chief Technical Officer August 17, 2026 Sell pre-set plan 16,767 $108.38 $1.8M
Durso Timothy August Chief Technical Officer August 17, 2026 Sell pre-set plan 16,306 $107.52 $1.8M
Durso Timothy August Chief Technical Officer August 17, 2026 Sell pre-set plan 7,918 $106.71 $844,930
Durso Timothy August Chief Technical Officer August 17, 2026 Sell pre-set plan 161 $111.28 $17,916

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

  • August 11, 2026
  • May 12, 2026
  • April 27, 2026
  • March 30, 2026

Recent SEC filings

Data status

When each part of this page on Veradermics, Inc was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Veradermics, Inc in brief

What does Veradermics, Inc do?
Veradermics, Inc is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Veradermics, Inc's stock ticker?
Veradermics, Inc trades under the ticker MANE on NYSE. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Veradermics, Inc's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Montanova Capital, LLC, FMR LLC and Sr One Capital Management, LP. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Are insiders buying or selling Veradermics, Inc stock?
Over the last 12 months, Veradermics, Inc's directors and officers reported 26 open-market purchases and 15 sales on Form 4. The insider trading page charts every trade.
When is Veradermics, Inc's next earnings date?
Around November 12, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Veradermics, Inc announces its own schedule.